Uriel Barkai

Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel.

International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States.

GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.

Biological Industries Israel Beit-Haemek Ltd. engages in the development and manufacture of cell culture media. Its products include Bio-Pure, BIOTARGET, EZ-PCR, EndoGo, and MSCgo. The company was founded in 1981 and is headquartered in Beit HaEmek, Israel.

Medicine On Line Israel (Moli) Ltd. is engaged in the field of diabetes . It focuses on: Improving the quality of life and medical treatment for people with diabetes, Performing educational activities, Producing scientific publications, and training people with diabetes. The association was founded by Ludwig Nelken, Herman Wolfson, Dr Liven, and Prof. A. M. Cohen in 1954 and is headquartered in Rishon Le-Zion, Israel.

Part of Pluri, Inc., Pluristem Ltd. is an Israeli company that sources therapeutic cells from the placenta to create cell-based products for commercial use. The company is based in Haifa, Israel and was founded by Yoram Nathan Drucker. The company's patented and validated 3D cell expansion system is designed to mimic the human body, and its cell therapies have potentially groundbreaking applications for treating ischemia, damaged muscle, hematology deficiencies, and inflammation. Pluristem's method is uniquely accurate, cost-effective, and consistent from batch to batch. Pluristem was acquired by Pluri, Inc. on June 23, 2003.